Tome Biosciences is a pioneering company in the field of genomic medicine, focusing on Programmable Genomic Integration, a cutting-edge technology that allows for the precise insertion of genetic sequences—of any size—into designated locations within the genome. This capability opens up new avenues in the development of advanced cell and gene therapies. By enabling the targeted rewriting of genetic code, Tome Biosciences is leading the charge toward potential cures for a wide range of genetic disorders. Their work not only aims to treat symptoms but to fundamentally alter the underlying genetic causes of disease, offering hope for long-lasting and potentially curative solutions for patients.